Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis
Launched by MICHAEL A. NAUCK · May 21, 2008
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
A new class of antidiabetic agents, the DPP-4 inhibitors, are thought to protect endogenously secreted incretin hormones (e.g., GLP-1 and GIP) from proteolytic degradation and inactivation. Since GLP-1 has antidiabetogenic properties, an augmentation of meal-related responses of intact, biologically active GLP-1 can be expected to increase the impact of incretin stimulation to insulin secretory responses. The incretin effect in type 2 diabetic patients is reduced due to an impaired secretion of GLP-1 and a reduced insulinotropic effectiveness of GIP. Therefore, sitagliptin (DPP-4 inhibitor)...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2-diabetes mellitus
- • BMI 25-35 kg/m2
- • HbA1c 6.5%-9% (without OHA medication)
- • HbA1c 6%-8.5% (OHA monotherapy with metformin or sulfonylurea)
- • Patient understands the study-procedures
- Exclusion Criteria:
- • Type 1-diabetes mellitus
- • C-peptide \< 0.7ng/mL (0.23 nmol/L)
- • Patient has been taking oral anti-hyperglycemic agent (OHA) within the prior 12 weeks, except metformin or a sulfonylurea
- • Patient has required insulin therapy within the past 12 weeks
About Michael A. Nauck
Michael A. Nauck is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical pharmacology and extensive experience in managing complex clinical studies, he specializes in the development of innovative treatments across various therapeutic areas. His dedication to rigorous scientific methodology and ethical standards ensures that all trials conducted under his sponsorship adhere to the highest quality benchmarks, fostering collaboration among research teams, regulatory bodies, and healthcare professionals. Michael A. Nauck's leadership and vision are pivotal in driving transformative healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Lauterberg, , Germany
Patients applied
Trial Officials
Michael A. Nauck, Prof. Dr.
Principal Investigator
Diabeteszentrum Bad Lauterberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials